Biotech Stocks Focused on Herbal Medicines Surge
This year, biotech stocks that concentrate on herbal remedies have seen a staggering increase of over 46,000%. Yet, the companies themselves report no revenues and are not particularly profitable.
A remarkable surge has propelled Regencell Bioscience Holdings Limited to a market valuation close to $30 billion as of April, starting from a mere penny stake. Just a year ago, its market capitalization was around $53 million, showing a 28% decline despite recording a net loss of $4.4 million for the fiscal year ending June 2024.
Earlier this month, the board announced a 38-for-1 stock split. Once this split took effect, the stock jumped an astonishing 283% in a single day, marking the largest one-day gain in nearly a year and causing over ten trading halts due to volatility.
The company’s shares have fluctuated wildly in 2025, plummeting 460 times without significant updates from the company itself. The Hong Kong-based firm, which entered the Nasdaq market in 2021, remains in the research and development phase and has yet to turn a profit since its founding, according to its annual filing with the U.S. Securities and Exchange Commission.
Regencell’s representatives have not responded to requests for comment.
Founded in the Cayman Islands, the company aims to address neurological disorders such as ADHD and autism spectrum disorder through traditional herb-based treatments, as stated on its website. Its traditional Chinese herbal medicine (TCM) formulations “contain only natural ingredients without synthetic components.”
In its October filing, the company noted that the revenue potential from TCM products may not be advantageous as they seek regulatory approvals, distribution channels, experience, and patent protections.
Additionally, Regencell is progressing on treatments for Covid-19, exploring a “holistic approach” in experimental therapies since 2022. They reported that data from the 2022 trials indicated effectiveness in reducing COVID symptoms within six days, although these findings have yet to undergo peer review.
Funding for the company’s operations largely comes from loans from shareholders, alongside revenues noted in their initial public offering records. As per SEC filings, total revenue from the IPO reached $21.85 million, supplemented by funds generated from the issuance of additional shares and the exercise of 325,000 shares.
